222 related articles for article (PubMed ID: 10217324)
21. Cisplatin nephrotoxicity and protection by silibinin.
Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
[TBL] [Abstract][Full Text] [Related]
22. The effect of fosfomycin on nedaplatin-induced nephrotoxicity in rats.
Yoshiyama Y; Yamaguchi K; Matsuo K; Kurokawa M; Kanke M
J Infect Chemother; 2005 Feb; 11(1):14-7. PubMed ID: 15729482
[TBL] [Abstract][Full Text] [Related]
23. Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.
Sack K; Herhahn J; Marre R; Schulz E
Infection; 1985; 13 Suppl 1():S156-60. PubMed ID: 3863794
[TBL] [Abstract][Full Text] [Related]
24. Histamine release induced by antimicrobial agents and effects of antimicrobial agents on vancomycin-induced histamine release from rat peritoneal mast cells.
Toyoguchi T; Ebihara M; Ojima F; Hosoya J; Shoji T; Nakagawa Y
J Pharm Pharmacol; 2000 Mar; 52(3):327-31. PubMed ID: 10757422
[TBL] [Abstract][Full Text] [Related]
25. Lipidomics Reveals Cisplatin-Induced Renal Lipid Alterations during Acute Kidney Injury and Their Attenuation by Cilastatin.
Moreno-Gordaliza E; Marazuela MD; Pastor Ó; Lázaro A; Gómez-Gómez MM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830406
[TBL] [Abstract][Full Text] [Related]
26. Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein.
Im DS; Shin HJ; Yang KJ; Jung SY; Song HY; Hwang HS; Gil HW
Toxicol Lett; 2017 Aug; 277():9-17. PubMed ID: 28549670
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
Chandrasekar PH; Levine DP; Price S; Rybak MJ
J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
[TBL] [Abstract][Full Text] [Related]
28. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
29. Cilastatin attenuates cisplatin-induced proximal tubular cell damage.
Camano S; Lazaro A; Moreno-Gordaliza E; Torres AM; de Lucas C; Humanes B; Lazaro JA; Milagros Gomez-Gomez M; Bosca L; Tejedor A
J Pharmacol Exp Ther; 2010 Aug; 334(2):419-29. PubMed ID: 20435919
[TBL] [Abstract][Full Text] [Related]
30. [Nephrotoxicity and drug interaction of vancomycin].
Toyoguchi T; Nakagawa Y; Watanabe H
Nihon Yakurigaku Zasshi; 1996 Feb; 107(2):53-66. PubMed ID: 8721008
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of elastase on cis-platinum-induced renal toxicity.
Suzuki M; Sekiguchi I; Tamada T; Tsuru S
Oncology; 1991; 48(6):474-9. PubMed ID: 1749585
[TBL] [Abstract][Full Text] [Related]
32. Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.
Humanes B; Jado JC; Camaño S; López-Parra V; Torres AM; Álvarez-Sala LA; Cercenado E; Tejedor A; Lázaro A
Biomed Res Int; 2015; 2015():704382. PubMed ID: 26504822
[TBL] [Abstract][Full Text] [Related]
33. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
[TBL] [Abstract][Full Text] [Related]
34. Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice.
Grochla I; Ko HL; Beuth J; Roszkowski K; Roszkowski W; Pulverer G
Zentralbl Bakteriol; 1990 Nov; 274(2):250-8. PubMed ID: 2085374
[TBL] [Abstract][Full Text] [Related]
35. The Nephroprotective Effect of N-Acetyl-L-Cysteine and Atorvastatin against Imipenem induced Nephrotoxicity.
Rababa’h AM; Hijjawi TB; Alzoubi KH; Al Demour S; Ababneh MA
Curr Mol Pharmacol; 2018; 11(2):155-161. PubMed ID: 28762308
[TBL] [Abstract][Full Text] [Related]
36. Ameliorative effect of flunarizine in cisplatin-induced acute renal failure via mitochondrial permeability transition pore inactivation in rats.
Muthuraman A; Sood S; Singla SK; Rana A; Singh A; Singh A; Singh J
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):57-64. PubMed ID: 21058009
[TBL] [Abstract][Full Text] [Related]
37. An overview of the pharmacology of imipenem/cilastatin.
Drusano GL
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():79-92. PubMed ID: 3546249
[TBL] [Abstract][Full Text] [Related]
38. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
Vos MC; Vincent HH; Yzerman EP
Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
40. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H
Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
